THE TOPIC

Discovery and innovation are the backbone of Pharma, Biotech and Medtech. Advances in digital and AI are accelerating research breakthroughs, triggering increasingly personalised and curative therapies. Gene editing, precision medicine, bi-specific antibodies, longevity research and many other areas offer previously unheard-of opportunities, but create also new challenges for regulators.

The environment for sector companies and healthcare providers is challenging. Sustainable practices in research, development, and manufacturing are gaining importance. Geopolitical tensions cause disruptions in supply chains and talent movements. Large pharma seeks innovative technologies and therapies, which can give rise to an M&A boom and make the environment even more competitive. Regulators and patients alike expect proven effectiveness of drugs and treatments, more value for money and more transparency.

Some say that we have already entered the golden age of Pharma, Biotech and Medtech, but what does it take to adapt to the ongoing and emerging changes?

THE PROGRAM

▶️ Hans-Jacob Bonnier, Chairman, Swedish-Polish Chamber of Commerce – “Welcome words”

▶️ Jon Arwidson, Healthcare Lead, Cecilia Fornstedt, Senior Healthcare Specialist, Alex Johnston, Healthcare consultant, PwC Sweden – “AI in healthcare: unlocking the full potential – strategies for a widespread adoption and success”

▶️ Henrik Holst , Account Executive for Life Sciences, Nexer Group & Beata Zubaka, Manager, Life Science Industry Portfolio, Holisticon Poland – “Supercharging Drug Discovery and Development with Tech Innovations”

▶️ Damian Adamczyk, Biotechnology Consulting Manager, Software Mind – “Current impact of AI on Life Sciences”

▶️ Victor Björk, Founder, Victor Björk Geroconsultancy – “Unlocking the prospects of longevity”

▶️ 🚀 Efi Ben Artzy, Entrepreneur, Investor, International Business Developer, Venture Builder for start-ups – “Challenges and opportunities in Medtech investments”

▶️ Panel discussion “Have we entered the golden age of Pharma, Biotech and Medtech?“:

• Marjo Puumalainen, International Director, SwedenBIO,
• Igor Dumbur, PMP, PSM I, ICP-DAS, Head of Delivery, ZONE3000,
• Katarzyna Hess-Wiktor, CEO, Minnity, Founder & CEO, Kapharos,
• Helena Rönqvist, Partner, Magnusson,
• Piotr Wyderski, COO, Spline,
• Karolina Maria Nowak, PhD, MBA, Director of Innovation and Biotechnology Development, Medical Research Agency

▶️ Networking and refreshments

Moderator: Victor Björk, Founder, Victor Björk Geroconsultancy